Metacrine Ownership 2024 | Who Owns Metacrine Now?


OverviewChart

Institutional Ownership

21.82%

Insider Ownership

14.78%

Retail Ownership

63.40%

Institutional Holders

5.00

Metacrine Institutional Shareholders


Institutional Shareholders by % of Total Shares

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
BML CAPITAL MANAGEMENT, LLC14.49%3.04%6,167,458--3,519,152,000Mar 31, 2023
JBF CAPITAL, INC.4.57%0.25%1,945,2701,945,270100.00%1,109,971,000Mar 31, 2023
ARTAL GROUP S.A.2.17%0.03%924,898--528,000Mar 31, 2023
TUDOR INVESTMENT CORP ET AL0.56%0.00%239,100-70,927-22.88%136,000Mar 31, 2023
WEDBUSH SECURITIES INC0.03%0.00%12,700--7,000Mar 31, 2023
BANK OF AMERICA CORP /DE/----40-100.00%-Mar 31, 2023
NEWSQUARE CAPITAL LLC----600-100.00%-Mar 31, 2023
TWO SIGMA SECURITIES, LLC----69,435-100.00%-Mar 31, 2023
WELLS FARGO & COMPANY/MN----241-100.00%-Mar 31, 2023
ALLWORTH FINANCIAL LP----500-100.00%-Mar 31, 2023
EDGE WEALTH MANAGEMENT LLC----11,000-100.00%-Mar 31, 2023
TWO SIGMA ADVISERS, LP----44,200-100.00%-Mar 31, 2023
NORTHERN TRUST CORP----26,163-100.00%-Mar 31, 2023
STATE STREET CORP----72,186-100.00%-Mar 31, 2023
BANK OF NEW YORK MELLON CORP----204,023-100.00%-Mar 31, 2023
RENAISSANCE TECHNOLOGIES LLC----574,636-100.00%-Mar 31, 2023
TOWER RESEARCH CAPITAL LLC (TRC)----18,413-100.00%-Mar 31, 2023
GEODE CAPITAL MANAGEMENT, LLC----76,235-100.00%-Mar 31, 2023
VANGUARD GROUP INC----254,492-100.00%-Mar 31, 2023
TANG CAPITAL MANAGEMENT LLC----4,250,000-100.00%-Mar 31, 2023

Metacrine's largest institutional shareholder is BML CAPITAL MANAGEMENT, LLC, holding 14.49% of the company's total share outstanding, currently valued at $3.52B. The top 10 institutional shareholders own together 21.82% of the company.

Institutional Shareholders by % of Total Assets

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
BML CAPITAL MANAGEMENT, LLC14.49%3.04%6,167,458--3,519,152,000Mar 31, 2023
JBF CAPITAL, INC.4.57%0.25%1,945,2701,945,270100.00%1,109,971,000Mar 31, 2023
ARTAL GROUP S.A.2.17%0.03%924,898--528,000Mar 31, 2023
TUDOR INVESTMENT CORP ET AL0.56%0.00%239,100-70,927-22.88%136,000Mar 31, 2023
WEDBUSH SECURITIES INC0.03%0.00%12,700--7,000Mar 31, 2023
BANK OF AMERICA CORP /DE/----40-100.00%-Mar 31, 2023
NEWSQUARE CAPITAL LLC----600-100.00%-Mar 31, 2023
TWO SIGMA SECURITIES, LLC----69,435-100.00%-Mar 31, 2023
WELLS FARGO & COMPANY/MN----241-100.00%-Mar 31, 2023
ALLWORTH FINANCIAL LP----500-100.00%-Mar 31, 2023
EDGE WEALTH MANAGEMENT LLC----11,000-100.00%-Mar 31, 2023
TWO SIGMA ADVISERS, LP----44,200-100.00%-Mar 31, 2023
NORTHERN TRUST CORP----26,163-100.00%-Mar 31, 2023
STATE STREET CORP----72,186-100.00%-Mar 31, 2023
BANK OF NEW YORK MELLON CORP----204,023-100.00%-Mar 31, 2023
RENAISSANCE TECHNOLOGIES LLC----574,636-100.00%-Mar 31, 2023
TOWER RESEARCH CAPITAL LLC (TRC)----18,413-100.00%-Mar 31, 2023
GEODE CAPITAL MANAGEMENT, LLC----76,235-100.00%-Mar 31, 2023
VANGUARD GROUP INC----254,492-100.00%-Mar 31, 2023
TANG CAPITAL MANAGEMENT LLC----4,250,000-100.00%-Mar 31, 2023

The largest Metacrine shareholder by % of total assets is BML CAPITAL MANAGEMENT, LLC. The company owns 6.17M shares of Metacrine (MTCR), representing 3.04% of its total assets.

Institutional Buyers

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
JBF CAPITAL, INC.4.57%0.25%1,945,2701,945,270100.00%1,109,971,000Mar 31, 2023
WEDBUSH SECURITIES INC0.03%0.00%12,700--7,000Mar 31, 2023
ARTAL GROUP S.A.2.17%0.03%924,898--528,000Mar 31, 2023
BML CAPITAL MANAGEMENT, LLC14.49%3.04%6,167,458--3,519,152,000Mar 31, 2023
BANK OF AMERICA CORP /DE/----40-100.00%-Mar 31, 2023
WELLS FARGO & COMPANY/MN----241-100.00%-Mar 31, 2023
MORGAN STANLEY----500-100.00%-Mar 31, 2023
ALLWORTH FINANCIAL LP----500-100.00%-Mar 31, 2023
NEWSQUARE CAPITAL LLC----600-100.00%-Mar 31, 2023
TRIFECTA CAPITAL ADVISORS, LLC----4,000-100.00%-Mar 31, 2023
UBS GROUP AG----4,781-100.00%-Mar 31, 2023
EDGE WEALTH MANAGEMENT LLC----11,000-100.00%-Mar 31, 2023
TOWER RESEARCH CAPITAL LLC (TRC)----18,413-100.00%-Mar 31, 2023
SUSQUEHANNA INTERNATIONAL GROUP, LLP----24,060-100.00%-Mar 31, 2023
NORTHERN TRUST CORP----26,163-100.00%-Mar 31, 2023
TWO SIGMA ADVISERS, LP----44,200-100.00%-Mar 31, 2023
TWO SIGMA SECURITIES, LLC----69,435-100.00%-Mar 31, 2023
TUDOR INVESTMENT CORP ET AL0.56%0.00%239,100-70,927-22.88%136,000Mar 31, 2023
STATE STREET CORP----72,186-100.00%-Mar 31, 2023
GEODE CAPITAL MANAGEMENT, LLC----76,235-100.00%-Mar 31, 2023

As of Mar 31 2023, Metacrine's largest institutional buyer is JBF CAPITAL, INC.. The company purchased 1.95M stocks of MTCR, valued at $1.11B.

Institutional Sellers

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
TANG CAPITAL MANAGEMENT LLC----4,250,000-100.00%-Mar 31, 2023
ARCH VENTURE MANAGEMENT, LLC----2,940,503-100.00%-Mar 31, 2023
RENAISSANCE TECHNOLOGIES LLC----574,636-100.00%-Mar 31, 2023
VANGUARD GROUP INC----254,492-100.00%-Mar 31, 2023
BANK OF NEW YORK MELLON CORP----204,023-100.00%-Mar 31, 2023
BLACKROCK INC.----100,444-100.00%-Mar 31, 2023
MILLENNIUM MANAGEMENT LLC----97,033-100.00%-Mar 31, 2023
JANE STREET GROUP, LLC----88,364-100.00%-Mar 31, 2023
GEODE CAPITAL MANAGEMENT, LLC----76,235-100.00%-Mar 31, 2023
STATE STREET CORP----72,186-100.00%-Mar 31, 2023
TUDOR INVESTMENT CORP ET AL0.56%0.00%239,100-70,927-22.88%136,000Mar 31, 2023
TWO SIGMA SECURITIES, LLC----69,435-100.00%-Mar 31, 2023
TWO SIGMA ADVISERS, LP----44,200-100.00%-Mar 31, 2023
NORTHERN TRUST CORP----26,163-100.00%-Mar 31, 2023
SUSQUEHANNA INTERNATIONAL GROUP, LLP----24,060-100.00%-Mar 31, 2023
TOWER RESEARCH CAPITAL LLC (TRC)----18,413-100.00%-Mar 31, 2023
EDGE WEALTH MANAGEMENT LLC----11,000-100.00%-Mar 31, 2023
UBS GROUP AG----4,781-100.00%-Mar 31, 2023
TRIFECTA CAPITAL ADVISORS, LLC----4,000-100.00%-Mar 31, 2023
NEWSQUARE CAPITAL LLC----600-100.00%-Mar 31, 2023

As of Mar 31 2023, Metacrine's biggest institutional seller is TANG CAPITAL MANAGEMENT LLC. The company sold -4.25M shares of MTCR, valued at -.

Institutional New positions

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
JBF CAPITAL, INC.4.57%0.25%1,945,2701,945,270100.00%1,109,971,000Mar 31, 2023

Metacrine's largest new institutional shareholder by number of shares is JBF CAPITAL, INC., purchased 1.95M shares, valued at $1.11B, as of undefined.

Institutional Sold Out

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
TANG CAPITAL MANAGEMENT LLC----4,250,000-100.00%-Mar 31, 2023
ARCH VENTURE MANAGEMENT, LLC----2,940,503-100.00%-Mar 31, 2023
RENAISSANCE TECHNOLOGIES LLC----574,636-100.00%-Mar 31, 2023
VANGUARD GROUP INC----254,492-100.00%-Mar 31, 2023
BANK OF NEW YORK MELLON CORP----204,023-100.00%-Mar 31, 2023
BLACKROCK INC.----100,444-100.00%-Mar 31, 2023
MILLENNIUM MANAGEMENT LLC----97,033-100.00%-Mar 31, 2023
JANE STREET GROUP, LLC----88,364-100.00%-Mar 31, 2023
GEODE CAPITAL MANAGEMENT, LLC----76,235-100.00%-Mar 31, 2023
STATE STREET CORP----72,186-100.00%-Mar 31, 2023
TWO SIGMA SECURITIES, LLC----69,435-100.00%-Mar 31, 2023
TWO SIGMA ADVISERS, LP----44,200-100.00%-Mar 31, 2023
NORTHERN TRUST CORP----26,163-100.00%-Mar 31, 2023
SUSQUEHANNA INTERNATIONAL GROUP, LLP----24,060-100.00%-Mar 31, 2023
TOWER RESEARCH CAPITAL LLC (TRC)----18,413-100.00%-Mar 31, 2023
EDGE WEALTH MANAGEMENT LLC----11,000-100.00%-Mar 31, 2023
UBS GROUP AG----4,781-100.00%-Mar 31, 2023
TRIFECTA CAPITAL ADVISORS, LLC----4,000-100.00%-Mar 31, 2023
NEWSQUARE CAPITAL LLC----600-100.00%-Mar 31, 2023
ALLWORTH FINANCIAL LP----500-100.00%-Mar 31, 2023
MORGAN STANLEY----500-100.00%-Mar 31, 2023
WELLS FARGO & COMPANY/MN----241-100.00%-Mar 31, 2023
BANK OF AMERICA CORP /DE/----40-100.00%-Mar 31, 2023

Metacrine's largest sold out institutional shareholder by shares sold is TANG CAPITAL MANAGEMENT LLC, sold -4.25M shares, valued at -, as of undefined.

Metacrine Mutual Fund Holders


Name% Total AssetsTotal SharesChange AmountChange %Date
MERIDIAN FUND INC0.12%432,584--Dec 29, 2023
BlackRock Advantage SMID Cap Fund, Inc.0.06%10,531--Dec 29, 2023
BRIDGEWAY FUNDS INC0.04%90,000--Dec 29, 2023
FIDELITY SELECT PORTFOLIOS0.00%312,500--Feb 29, 2024
DEUTSCHE DWS INVESTMENTS VIT FUNDS0.00%1,018--Dec 31, 2023
SEASONS SERIES TRUST0.00%26,725--Dec 31, 2023
VANGUARD INDEX FUNDS0.00%254,492--Dec 31, 2023
SCHWAB CAPITAL TRUST0.00%13,800--Feb 29, 2024
FIDELITY CONCORD STREET TRUST0.00%66,850--Feb 29, 2024
Calvert Variable Products, Inc.0.00%555--Dec 31, 2023
VANGUARD INSTITUTIONAL INDEX FUNDS0.00%2,323--Dec 31, 2023
FIDELITY SALEM STREET TRUST0.00%48,410--Feb 29, 2024
SEI INSTITUTIONAL MANAGED TRUST0.00%52,751--Dec 31, 2023
ProFunds0.00%143--Jan 31, 2024
STATE STREET INSTITUTIONAL INVESTMENT TRUST0.00%1,200--Dec 31, 2023
VALIC Co I0.00%3,138--Feb 29, 2024
VANGUARD SCOTTSDALE FUNDS0.00%20,412--Feb 29, 2024
NATIONWIDE VARIABLE INSURANCE TRUST0.00%1,193--Dec 31, 2023
Dimensional ETF Trust0.00%3,360--Jan 31, 2024
NORTHERN FUNDS0.00%4,210--Dec 29, 2023
NATIONWIDE MUTUAL FUNDS0.00%545--Jan 31, 2024
T. Rowe Price Index Trust, Inc.0.00%59--Feb 29, 2024
COLLEGE RETIREMENT EQUITIES FUND0.00%3,798--Dec 31, 2023
EQ ADVISORS TRUST0.00%3,071--Dec 31, 2023
iSHARES TRUST0.00%36,356--Feb 29, 2024
SUNAMERICA SERIES TRUST0.00%715--Jan 31, 2024
PACIFIC SELECT FUND0.00%4,716--Dec 31, 2023
BlackRock Variable Series Funds, Inc.0.00%4,751--Dec 31, 2023
MASSMUTUAL SELECT FUNDS0.00%819--Dec 31, 2023
JOHN HANCOCK VARIABLE INSURANCE TRUST0.00%1,025--Dec 31, 2023
Bridge Builder Trust0.00%2,178--Dec 31, 2023
BLACKROCK FUNDS0.00%1,284--Feb 29, 2024
PRINCIPAL FUNDS, INC.0.00%1,123--Feb 29, 2024
SEI INSTITUTIONAL INVESTMENTS TRUST0.00%2,793--Feb 29, 2024

Metacrine's largest mutual fund holder by % of total assets is "MERIDIAN FUND INC", owning 432.58K shares, compromising 0.12% of its total assets.

Metacrine Institutional Ownership Trends


Institutional Holdings Trend

DateHoldingsChange %
31 Mar, 235-80.77%
31 Dec, 222623.81%
30 Sep, 22215.00%
30 Jun, 2220-31.03%
31 Mar, 2229-3.33%
31 Dec, 2130-6.25%
30 Sep, 2132-17.95%
30 Jun, 2139-15.22%
31 Mar, 214612.20%
31 Dec, 204157.69%
30 Sep, 2026-

As of 31 Mar 23, 5 institutions are holding Metacrine's shares, representing a decrease of -80.77% compared to the previous quarter.

Shares Outstanding Trend

DateShares OutstandingChange %
31 Mar, 239,289,426-42.84%
31 Dec, 2216,252,872101.77%
30 Sep, 228,055,00732.59%
30 Jun, 226,074,908-2.89%
31 Mar, 226,255,73190.66%
31 Dec, 213,281,110-70.19%
30 Sep, 2111,007,432-11.73%
30 Jun, 2112,470,294-5.81%
31 Mar, 2113,238,958-0.29%
31 Dec, 2013,276,809-2.19%
30 Sep, 2013,573,652-

Metacrine (MTCR) has 9.29M shares outstanding as of 31 Mar 23, down -42.84% compared to the previous quarter.

Institutional Ownership Trend

DateOwnership %Change %
31 Mar, 2321.82%1.50%
31 Dec, 2238.18%10.66%
30 Sep, 2218.92%9.23%
30 Jun, 2214.32%6.49%
31 Mar, 2214.85%24.46%
31 Dec, 217.79%0.45%
30 Sep, 2141.50%1.86%
30 Jun, 2147.29%1.85%
31 Mar, 2150.51%1.93%
31 Dec, 2051.12%1.87%
30 Sep, 2052.27%-

As of 31 Mar 23, Metacrine is held by 21.82% institutional shareholders, representing a 1.50% growth compared to 31 Dec 22.

Institutional Increased Positions Trend

DateIncreased PositionsChange %
31 Mar, 231-90.91%
31 Dec, 221137.50%
30 Sep, 22860.00%
30 Jun, 225-73.68%
31 Mar, 221911.76%
31 Dec, 211713.33%
30 Sep, 2115-11.76%
30 Jun, 2117-
31 Mar, 2117-41.38%
31 Dec, 202911.54%
30 Sep, 2026-

1 institutional shareholders have increased their position in MTCR stock as of 31 Mar 23 compared to 11 in the previous quarter (a -90.91% decrease).

Institutional Reduced Positions Trend

DateReduced PositionsChange %
31 Mar, 231-83.33%
31 Dec, 22650.00%
30 Sep, 224-50.00%
30 Jun, 228100.00%
31 Mar, 224-20.00%
31 Dec, 215-37.50%
30 Sep, 218-38.46%
30 Jun, 2113-13.33%
31 Mar, 2115150.00%
31 Dec, 206-
30 Sep, 20--

1 institutional shareholders have reduced their position in MTCR stock as of 31 Mar 23 compared to 6 in the previous quarter (a -83.33% decrease).

All Institutional Ownership Trend Data

DateHoldingsChange %Shares OutstandingChange %Ownership %Change %Increased PositionsChange %Reduced PositionsChange %
31 Mar, 235-80.77%9,289,426-42.84%21.82%1.50%1-90.91%1-83.33%
31 Dec, 222623.81%16,252,872101.77%38.18%10.66%1137.50%650.00%
30 Sep, 22215.00%8,055,00732.59%18.92%9.23%860.00%4-50.00%
30 Jun, 2220-31.03%6,074,908-2.89%14.32%6.49%5-73.68%8100.00%
31 Mar, 2229-3.33%6,255,73190.66%14.85%24.46%1911.76%4-20.00%
31 Dec, 2130-6.25%3,281,110-70.19%7.79%0.45%1713.33%5-37.50%
30 Sep, 2132-17.95%11,007,432-11.73%41.50%1.86%15-11.76%8-38.46%
30 Jun, 2139-15.22%12,470,294-5.81%47.29%1.85%17-13-13.33%
31 Mar, 214612.20%13,238,958-0.29%50.51%1.93%17-41.38%15150.00%
31 Dec, 204157.69%13,276,809-2.19%51.12%1.87%2911.54%6-
30 Sep, 2026-13,573,652-52.27%-26---

Metacrine Insider Shareholders Trades


Open Market Insider Trades

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource
Jan 27, 2023York Michaelofficer Chief Business OfficerS-SaleSell107,054$0.41$44.33K103,499
Jan 27, 2023Klassen Prestonofficer President & CEOS-SaleSell380,605$0.41$157.27K541,905
Dec 21, 2022Leonard Braden Michaeldirector-P-PurchaseBuy120,099$0.40$48.04K6,160,570
Dec 21, 2022Leonard Braden Michaeldirector-P-PurchaseBuy50,122$0.38$19.00K6,040,471
Dec 21, 2022Leonard Braden Michaeldirector-P-PurchaseBuy101,384$0.40$40.55K5,990,349
Nov 09, 2022Leonard Braden Michaeldirector-P-PurchaseBuy39,816$0.39$15.53K5,888,965
Nov 09, 2022Leonard Braden Michaeldirector-P-PurchaseBuy500$0.40$200.005,849,149
Nov 09, 2022Leonard Braden Michaeldirector-P-PurchaseBuy123,954$0.42$52.35K5,848,649
Oct 31, 2022Leonard Braden Michaeldirector-P-PurchaseBuy45,022$0.40$18.00K5,724,695
Oct 31, 2022Leonard Braden Michaeldirector-P-PurchaseBuy767,507$0.39$299.33K5,679,673
Oct 26, 2022Leonard Braden Michaeldirector-P-PurchaseBuy588,533$0.35$208.22K4,912,166
Oct 26, 2022Leonard Braden Michaeldirector-P-PurchaseBuy499,279$0.35$175.60K4,323,633
Oct 26, 2022Leonard Braden Michaeldirector-P-PurchaseBuy174,354$0.34$59.28K3,824,354

Open Market Insider Buys

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource
Dec 21, 2022Leonard Braden Michaeldirector-P-PurchaseBuy120,099$0.40$48.04K6,160,570
Dec 21, 2022Leonard Braden Michaeldirector-P-PurchaseBuy50,122$0.38$19.00K6,040,471
Dec 21, 2022Leonard Braden Michaeldirector-P-PurchaseBuy101,384$0.40$40.55K5,990,349
Nov 09, 2022Leonard Braden Michaeldirector-P-PurchaseBuy39,816$0.39$15.53K5,888,965
Nov 09, 2022Leonard Braden Michaeldirector-P-PurchaseBuy500$0.40$200.005,849,149
Nov 09, 2022Leonard Braden Michaeldirector-P-PurchaseBuy123,954$0.42$52.35K5,848,649
Oct 31, 2022Leonard Braden Michaeldirector-P-PurchaseBuy45,022$0.40$18.00K5,724,695
Oct 31, 2022Leonard Braden Michaeldirector-P-PurchaseBuy767,507$0.39$299.33K5,679,673
Oct 26, 2022Leonard Braden Michaeldirector-P-PurchaseBuy588,533$0.35$208.22K4,912,166
Oct 26, 2022Leonard Braden Michaeldirector-P-PurchaseBuy499,279$0.35$175.60K4,323,633
Oct 26, 2022Leonard Braden Michaeldirector-P-PurchaseBuy174,354$0.34$59.28K3,824,354

Insider Sells

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource
Mar 24, 2023Klassen Prestondirector-A-AwardSell842,211$0.47$395.84K1,384,116
Mar 24, 2023Klassen Prestondirector-D-ReturnSell842,211$0.47$395.84K-
Jan 27, 2023York Michaelofficer Chief Business OfficerS-SaleSell107,054$0.41$44.33K103,499
Jan 27, 2023Klassen Prestonofficer President & CEOS-SaleSell380,605$0.41$157.27K541,905
Oct 26, 2022Leonard Braden Michaeldirector-Sell---600,000

All Insider Owners Trades

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource
Mar 24, 2023Klassen Prestondirector-A-AwardSell842,211$0.47$395.84K1,384,116
Mar 24, 2023Klassen Prestondirector-D-ReturnSell842,211$0.47$395.84K-
Jan 27, 2023York Michaelofficer Chief Business OfficerS-SaleSell107,054$0.41$44.33K103,499
Jan 27, 2023Klassen Prestonofficer President & CEOS-SaleSell380,605$0.41$157.27K541,905
Dec 21, 2022Leonard Braden Michaeldirector-P-PurchaseBuy120,099$0.40$48.04K6,160,570
Dec 21, 2022Leonard Braden Michaeldirector-P-PurchaseBuy50,122$0.38$19.00K6,040,471
Dec 21, 2022Leonard Braden Michaeldirector-P-PurchaseBuy101,384$0.40$40.55K5,990,349
Nov 09, 2022Leonard Braden Michaeldirector-P-PurchaseBuy39,816$0.39$15.53K5,888,965
Nov 09, 2022Leonard Braden Michaeldirector-P-PurchaseBuy500$0.40$200.005,849,149
Nov 09, 2022Leonard Braden Michaeldirector-P-PurchaseBuy123,954$0.42$52.35K5,848,649
Oct 31, 2022Leonard Braden Michaeldirector-P-PurchaseBuy45,022$0.40$18.00K5,724,695
Oct 31, 2022Leonard Braden Michaeldirector-P-PurchaseBuy767,507$0.39$299.33K5,679,673
Oct 26, 2022Leonard Braden Michaeldirector-P-PurchaseBuy588,533$0.35$208.22K4,912,166
Oct 26, 2022Leonard Braden Michaeldirector-P-PurchaseBuy499,279$0.35$175.60K4,323,633
Oct 26, 2022Leonard Braden Michaeldirector-P-PurchaseBuy174,354$0.34$59.28K3,824,354
Oct 26, 2022Leonard Braden Michaeldirector-Buy---3,824,354
Oct 26, 2022Leonard Braden Michaeldirector-Sell---600,000
Sep 06, 2022Nashat Amirdirector A-AwardBuy16,500--16,500
Sep 06, 2022Nashat Amirdirector, 10 percent owner A-AwardBuy16,500$0.42$6.93K16,500
Sep 06, 2022JONKER JEFFREY DAVIDdirector A-AwardBuy16,500--16,500

The last insider sell of Metacrine's stock was made by Klassen Preston on Mar 24 2023, selling 842,211 shares at $0.47 per share (valued at $395.84K). The last insider buy of MTCR was made by Leonard Braden Michael on Dec 21 2022, buying 120,099 shares at $0.40 per share (worth $48.04K).

Metacrine Insider Ownership Trends


All Insider Trades Trend

DateBuySellBuy/Sell Ratio
Q1 2023-4-
Q4 20221111100.00%
Q2 202281800.00%
Q1 202241400.00%
Q4 2021-29-
Q2 202113--
Q1 20215--
Q4 2020-1-
Q3 20206666100.00%

0 total buy trades, and 4 total sell trades (buy/sell ratio of 0.00%) were made by Metacrine's insiders, as of Q1 2023.

Open Market Insider Trades Trend

DateBuySellBuy/Sell Ratio
Q1 2023-2-
Q4 202211--
Q2 2022-1-
Q1 2022---
Q4 2021-29-
Q2 20212--
Q1 2021---
Q4 2020---
Q3 202021--

As of Q1 2023, Insider owners conducted 0 open market buy trades and 2 open market sell trades of Metacrine's stocks.

Metacrine Peer Ownership


TickerCompany
ANEBAnebulo Pharmaceuticals, Inc.
SRZNSurrozen, Inc.
TILInstil Bio, Inc.
MGTADianthus Therapeutics, Inc.
NUVBNuvation Bio Inc.
INDPIndaptus Therapeutics, Inc.
TCONTRACON Pharmaceuticals, Inc.
CTMXCytomX Therapeutics, Inc.
MNPRMonopar Therapeutics Inc.
TARAProtara Therapeutics, Inc.
NLTXNeurogene Inc.
ASMBAssembly Biosciences, Inc.
VCNXVaccinex, Inc.

MTCR Ownership FAQ


Metacrine is owned by institutional shareholders (21.82%), insiders (14.78%), and public (63.40%). The largest institutional shareholder of Metacrine is BML CAPITAL MANAGEMENT, LLC (14.49% of total shares) and the top mutual fund owner is MERIDIAN FUND INC (0.12% of total shares).

Metacrine's major institutional shareholders are BML CAPITAL MANAGEMENT, LLC, JBF CAPITAL, INC., ARTAL GROUP S.A., TUDOR INVESTMENT CORP ET AL, and WEDBUSH SECURITIES INC. The top five shareholders own together 21.82% of the company's share outstanding.

As of Mar 2023, there are 5 institutional shareholders of Metacrine.

BML CAPITAL MANAGEMENT, LLC owns 6.17M shares of Metacrine, representing 14.49% of the company's total shares outstanding, valued at $3.52B (as of Mar 2023).

As of Mar 2023, JBF CAPITAL, INC holds 1.95M shares of Metacrine (MTCR), compromising 4.57% of the company, valued at $1.11B.

ARTAL GROUP S.A is the third largest holder of Metacrine. The company owns 924.9K of the company's shares outstanding (worth $528K).